Bowman-Birk Protease Inhibitor Induces Tr1 Cells And Suppress Effector Phase Of EAE Disease; A Potential NOVEL Therapy For Multiple Sclerosis (P1.183)

Farinaz Safavi,Javad Rasouli,Elisabeth Mari,Guang-Xian Zhang,Mohamad Rostami

DOI: https://doi.org/10.1212/wnl.82.10_supplement.p1.183

IF: 9.9

2014-01-01

Neurology

Abstract:Background;Multiple Sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system and second cause of disability in young adults. An effective and well tolerated oral agent without associated immunosuppression is highly desirable as monotherapy or for use in combination with other MS-modifying agents for treatment of multiple sclerosis. BBI is a small (8 kD) serine protease inhibitor derived from soybeans, with pronounced anti-inflammatory effects. Our previous studies have shown that oral BBI dramatically reduces autoimmune inflammation of the CNS in Experimental Autoimmune Encephalomyelitis (EAE), resulting in amelioration of clinical disease and significant reduction of inflammation, demyelination and axonal loss. Here, we present that BBI acts on T cells and induce Tr1 cells with high ability of IL-10 production causes suppression of effector phase of EAE disease. BBI also decreases number of pathogenic infiltrating T cells into the CNS. In terms of mechanisms of action, BBI does not act through IL-27 signaling pathway but induces IL-10 and Tr1 cells through t-bet and stat-1 transcription factors. Additionally, it enhances expression of c-maf, a major Tr1 transcription factor, and IL-21 a necessary cytokine for Tr1 maintenance. Furthermore, BBI induces IL-10 production in human CD4+T cells which makes it a promising candidate for treatment of multiple sclerosis. Disclosure: Dr. Safavi has nothing to disclose. Dr. Rasouli has nothing to disclose. Dr. Mari has nothing to disclose. Dr. Zhang has nothing to disclose. Dr. Rostami has nothing to disclose.